From Gila Monster Venom to Global Phenomenon: The History of GLP-1s

It is rare to see a class of medication dominate the cultural conversation as rapidly as GLP-1 receptor agonists have. The science behind them is the result of over 40 years of meticulous research, serendipitous discovery, and a surprising detour through the desert.

The 1980s: Identifying the "Incretin" Effect

Researchers noticed that oral glucose consumption produced a much higher insulin response than intravenous glucose. This suggested something in the gut was signaling the pancreas. They identified two key hormones: GIP and GLP-1.

The 1990s: The Gila Monster Connection

In 1992, Dr. John Eng identified a peptide called exendin-4 in Gila monster venom. It was structurally similar to human GLP-1 but significantly more stable — remaining active for hours instead of minutes. This was the "Eureka!" moment proving a long-acting version was possible.

The 2000s: From Diabetes to Weight Loss

The first breakthrough came in 2005 with FDA approval of exenatide, the synthetic version of the Gila monster peptide, initially as a diabetes medication.

The Serendipitous Observation

During Type 2 diabetes trials, patients reported an unexpected "side effect": weight loss. Researchers realized GLP-1 receptors in the brain influenced the hypothalamus's satiety center.

The 2020s: The Era of Potency

Newer iterations like semaglutide (2021) and tirzepatide (2022/2023, a dual GIP/GLP-1 agonist) are far more potent with once-weekly dosing. The paradigm has shifted from "treating diabetes" to "treating metabolic disease."

Looking Forward

The field is exploring oral versions and triple-agonist combinations targeting GLP-1, GIP, and Glucagon receptors simultaneously.

Disclaimer: This article is for informational purposes only. Always consult a medical professional for personal health advice.